



CLAIMS

1. A compound of the following formula (I)




wherein:


R^1 and R^2 are joined together to form a moiety (A1), (A2) or (A3):



(A1)




(A2)




(A3);

R^3 and R^4 are joined together to form a moiety (B1), or R^3 is a moiety (B2) and R^4 is $-NH_3$, or R^3 and R^4 are each $-NH_3$:



(B1)



(B2);

R⁵ is -N(R⁵¹)- or -CH₂-;

R⁵¹ is hydrogen or C₁₋₈ alkyl;

R⁶ is C₁₋₈ alkylene, wherein one or two -CH₂- units comprised in said C₁₋₈ alkylene are each optionally replaced by a group independently selected from -O-, -CO-, -C(=O)O-, -O-C(=O)-, -N(R⁶¹)-, -N(R⁶¹)-CO-, -CO-N(R⁶¹)-, arylene, and heteroarylene, wherein said arylene and said heteroarylene are each optionally substituted with one or more groups R⁶²;

each R⁶¹ is independently selected from hydrogen and C₁₋₈ alkyl;

each R⁶² is independently selected from C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, -(C₀₋₃ alkylene)-OH, -(C₀₋₃ alkylene)-O(C₁₋₈ alkyl), -(C₀₋₃ alkylene)-SH, -(C₀₋₃ alkylene)-S(C₁₋₈ alkyl), -(C₀₋₃ alkylene)-NH₂, -(C₀₋₃ alkylene)-NH(C₁₋₈ alkyl), -(C₀₋₃ alkylene)-N(C₁₋₈ alkyl)(C₁₋₈ alkyl), -(C₀₋₃ alkylene)-halogen, -(C₀₋₃ alkylene)-(C₁₋₈ haloalkyl), -(C₀₋₃ alkylene)-CF₃, -(C₀₋₃ alkylene)-CN, -(C₀₋₃ alkylene)-CHO, -(C₀₋₃ alkylene)-CO-(C₁₋₈ alkyl), -(C₀₋₃ alkylene)-COOH, -(C₀₋₃ alkylene)-CO-O-(C₁₋₈ alkyl), -(C₀₋₃ alkylene)-O-CO-(C₁₋₈ alkyl), -(C₀₋₃ alkylene)-CO-NH₂, -(C₀₋₃ alkylene)-CO-NH(C₁₋₈ alkyl), -(C₀₋₃ alkylene)-CO-N(C₁₋₈ alkyl)(C₁₋₈ alkyl), -(C₀₋₃ alkylene)-NH-CO-(C₁₋₈ alkyl), -(C₀₋₃ alkylene)-N(C₁₋₈ alkyl)-CO-(C₁₋₈ alkyl), -(C₀₋₃ alkylene)-SO₂-NH₂, -(C₀₋₃ alkylene)-SO₂-NH(C₁₋₈ alkyl), -(C₀₋₃ alkylene)-SO₂-N(C₁₋₈ alkyl)(C₁₋₈ alkyl), -(C₀₋₃ alkylene)-NH-SO₂-(C₁₋₈ alkyl), and -(C₀₋₃ alkylene)-N(C₁₋₈ alkyl)-SO₂-(C₁₋₈ alkyl);

R⁷ is selected from hydrogen, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -O-(C₁₋₈ alkyl), -O-(C₂₋₈ alkenyl), -O-(C₂₋₈ alkynyl), -O-cycloalkyl, -O-heterocycloalkyl, -O-aryl, -O-heteroaryl, -N(R⁷¹)-(C₁₋₈ alkyl), -N(R⁷¹)-(C₂₋₈ alkenyl), -N(R⁷¹)-(C₂₋₈ alkynyl), -N(R⁷¹)-cycloalkyl, -N(R⁷¹)-heterocycloalkyl, -N(R⁷¹)-aryl, and -N(R⁷¹)-heteroaryl, wherein said C₁₋₈ alkyl or the C₁₋₈ alkyl moiety comprised in any of the aforementioned groups, said C₂₋₈ alkenyl or the C₂₋₈ alkenyl moiety comprised in any of the aforementioned groups, and said C₂₋₈ alkynyl or the C₂₋₈ alkynyl moiety comprised in any of the aforementioned groups are each optionally substituted with one or more groups R⁷², and further wherein said cycloalkyl or the cycloalkyl moiety comprised in any of the aforementioned groups, said heterocycloalkyl or the heterocycloalkyl

moiety comprised in any of the aforementioned groups, said aryl or the aryl moiety comprised in any of the aforementioned groups, and said heteroaryl or the heteroaryl moiety comprised in any of the aforementioned groups are each optionally substituted with one or more groups R^{73} ;

each R^{71} is independently selected from hydrogen and C_{1-8} alkyl;

each R^{72} is independently selected from -OH, -O(C_{1-8} alkyl), -SH, -S(C_{1-8} alkyl), -NH₂, -NH(C_{1-8} alkyl), -N(C_{1-8} alkyl)(C_{1-8} alkyl), halogen, C_{1-8} haloalkyl, -CF₃, -CN, -CHO, -CO-(C_{1-8} alkyl), -COOH, -CO-O-(C_{1-8} alkyl), -O-CO-(C_{1-8} alkyl), -CO-NH₂, -CO-NH(C_{1-8} alkyl), -CO-N(C_{1-8} alkyl)(C_{1-8} alkyl), -NH-CO-(C_{1-8} alkyl), -N(C_{1-8} alkyl)-CO-(C_{1-8} alkyl), -SO₂-NH₂, -SO₂-NH(C_{1-8} alkyl), -SO₂-N(C_{1-8} alkyl)(C_{1-8} alkyl), -NH-SO₂-(C_{1-8} alkyl), and -N(C_{1-8} alkyl)-SO₂-(C_{1-8} alkyl);

each R^{73} is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, -(C_{0-3} alkylene)-OH, -(C_{0-3} alkylene)-O(C_{1-8} alkyl), -(C_{0-3} alkylene)-SH, -(C_{0-3} alkylene)-S(C_{1-8} alkyl), -(C_{0-3} alkylene)-NH₂, -(C_{0-3} alkylene)-NH(C_{1-8} alkyl), -(C_{0-3} alkylene)-N(C_{1-8} alkyl)(C_{1-8} alkyl), -(C_{0-3} alkylene)-halogen, -(C_{0-3} alkylene)-(C_{1-8} haloalkyl), -(C_{0-3} alkylene)-CF₃, -(C_{0-3} alkylene)-CN, -(C_{0-3} alkylene)-CHO, -(C_{0-3} alkylene)-CO-(C_{1-8} alkyl), -(C_{0-3} alkylene)-COOH, -(C_{0-3} alkylene)-CO-O-(C_{1-8} alkyl), -(C_{0-3} alkylene)-O-CO-(C_{1-8} alkyl), -(C_{0-3} alkylene)-CO-NH₂, -(C_{0-3} alkylene)-CO-NH(C_{1-8} alkyl), -(C_{0-3} alkylene)-CO-N(C_{1-8} alkyl)(C_{1-8} alkyl), -(C_{0-3} alkylene)-NH-CO-(C_{1-8} alkyl), -(C_{0-3} alkylene)-N(C_{1-8} alkyl)-CO-(C_{1-8} alkyl), -(C_{0-3} alkylene)-SO₂-NH₂, -(C_{0-3} alkylene)-SO₂-NH(C_{1-8} alkyl), -(C_{0-3} alkylene)-SO₂-N(C_{1-8} alkyl)(C_{1-8} alkyl), -(C_{0-3} alkylene)-NH-SO₂-(C_{1-8} alkyl), and -(C_{0-3} alkylene)-N(C_{1-8} alkyl)-SO₂-(C_{1-8} alkyl);

each R^8 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, -OH, -O-(C_{1-8} alkyl), -SH, -S-(C_{1-8} alkyl), -NH₂, -NH(C_{1-8} alkyl), -N(C_{1-8} alkyl)(C_{1-8} alkyl), halogen, C_{1-8} haloalkyl, -CF₃, -CN, -CHO, -CO-(C_{1-8} alkyl), -COOH, -CO-O-(C_{1-8} alkyl), -O-CO-(C_{1-8} alkyl), -CO-NH₂, -CO-NH(C_{1-8} alkyl), -CO-N(C_{1-8} alkyl)(C_{1-8} alkyl), -NH-CO-(C_{1-8} alkyl), -N(C_{1-8} alkyl)-CO-(C_{1-8} alkyl), -SO₂-NH₂, -SO₂-NH(C_{1-8} alkyl), -SO₂-N(C_{1-8} alkyl)(C_{1-8} alkyl), -NH-SO₂-(C_{1-8} alkyl), and -N(C_{1-8} alkyl)-SO₂-(C_{1-8} alkyl);

each R^9 is independently selected from C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, -OH, -O-(C_{1-8} alkyl), -SH, -S-(C_{1-8} alkyl), -NH₂, -NH(C_{1-8} alkyl), -N(C_{1-8} alkyl)(C_{1-8} alkyl),

halogen, C₁₋₈ haloalkyl, -CF₃, -CN, -CHO, -CO-(C₁₋₈ alkyl), -COOH, -CO-O-(C₁₋₈ alkyl), -O-CO-(C₁₋₈ alkyl), -CO-NH₂, -CO-NH(C₁₋₈ alkyl), -CO-N(C₁₋₈ alkyl)(C₁₋₈ alkyl), -NH-CO-(C₁₋₈ alkyl), -N(C₁₋₈ alkyl)-CO-(C₁₋₈ alkyl), -SO₂-NH₂, -SO₂-NH(C₁₋₈ alkyl), -SO₂-N(C₁₋₈ alkyl)(C₁₋₈ alkyl), -NH-SO₂-(C₁₋₈ alkyl), and -N(C₁₋₈ alkyl)-SO₂-(C₁₋₈ alkyl);


n is an integer of 0 to 8; and

m is an integer of 0 to 6;

or a pharmaceutically acceptable salt or solvate thereof.

2. The compound of claim 1, wherein R¹ and R² are joined together to form a moiety (A1).
3. The compound of claim 1 or 2, wherein R³ and R⁴ are joined together to form a moiety (B1).
4. The compound of any one of claims 1 to 3, wherein R⁵ is -NH-, -N(-CH₃)- or -N(-CH₂CH₃)-.
5. The compound of any one of claims 1 to 4, wherein R⁶ is C₁₋₈ alkylene.
6. The compound of any one of claims 1 to 5, wherein R⁶ is selected from -CH₂-, -(CH₂)₂-, -(CH₂)₃-, -(CH₂)₄-, and -(CH₂)₅-.
7. The compound of any one of claims 1 to 6, wherein R⁷ is selected from C₁₋₈ alkyl, C₂₋₈ alkenyl, and C₂₋₈ alkynyl.
8. The compound of any one of claims 1 to 7, wherein R⁷ is C₁₋₅ alkyl.
9. The compound of any one of claims 1 to 8, wherein n and m are each 0.
10. The compound of any one of claims 1 to 8, wherein R³ and R⁴ are joined together to form a moiety (B1), and wherein n is 1, 2, 3 or 4.
11. The compound of claim 10, wherein n is 1.


12. The compound of claim 10, wherein n is 1 and R^8 is methyl.
13. The compound of any one of claims 1 to 12, wherein R^1 and R^2 are joined together to form a moiety (A1), and wherein R^3 and R^4 are joined together to form a moiety (B1).
14. The compound of claim 1, wherein R^1 and R^2 are joined together to form a moiety (A1), wherein R^3 and R^4 are joined together to form a moiety (B1), wherein R^5 is $-NH-$, and wherein R^6 is C_{1-8} alkylene;
with the proviso that the following compounds and pharmaceutically acceptable salts thereof are excluded:




15. The compound of claim 14, wherein R^6 is selected from $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, and $-(CH_2)_5-$.
16. The compound of claim 14, wherein R^6 is $-(CH_2)_2-$.
17. The compound of claim 1, wherein R^1 and R^2 are joined together to form a moiety (A2) or (A3).
18. The compound of claim 1 or 17, wherein R^1 and R^2 are joined together to form a moiety (A2).
19. The compound of claim 1 or 17, wherein R^1 and R^2 are joined together to form a moiety (A2), and wherein R^3 and R^4 are joined together to form a moiety (B1).
20. The compound of claim 1 or 17, wherein R^1 and R^2 are joined together to form a moiety (A2), and wherein R^3 and R^4 are each $-NH_3$.

21. The compound of claim 1 or 17, wherein R^1 and R^2 are joined together to form a moiety (A3).
22. The compound of any one of claims 17 to 21, wherein R^5 is $-NH-$, $-N(-CH_3)-$ or $-N(-CH_2CH_3)-$.
23. The compound of any one of claims 17 to 22, wherein R^6 is C_{1-8} alkylene.
24. The compound of any one of claims 17 to 23, wherein R^6 is selected from $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, and $-(CH_2)_5-$.
25. The compound of any one of claims 17 to 24, wherein R^7 is selected from C_{1-8} alkyl, C_{2-8} alkenyl, and C_{2-8} alkynyl.
26. The compound of any one of claims 17 to 25, wherein R^7 is C_{1-5} alkyl.
27. The compound of any one of claims 17 to 26, wherein n and m are each 0.
28. The compound of claim 1, wherein R^3 is a moiety (B2) and R^4 is $-NH_3$.
29. The compound of claim 28, wherein R^1 and R^2 are joined together to form a moiety (A1) or (A2).
30. The compound of claim 28 or 29, wherein R^5 is $-NH-$, $-N(-CH_3)-$ or $-N(-CH_2CH_3)-$.
31. The compound of any one of claims 28 to 30, wherein R^6 is C_{1-8} alkylene.
32. The compound of any one of claims 28 to 31, wherein R^6 is selected from $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, and $-(CH_2)_5-$.
33. The compound of any one of claims 28 to 32, wherein R^7 is selected from C_{1-8} alkyl, C_{2-8} alkenyl, and C_{2-8} alkynyl.
34. The compound of any one of claims 28 to 33, wherein R^7 is C_{1-5} alkyl.
35. The compound of any one of claims 28 to 34, wherein n and m are each 0.


36. The compound of claim 1, which is a compound having any one of the following formulae:




KP2299




17




18



19




20




21


87




22




23




24



31




32




33


88




34




35




36




37




38




39



40







41






or a pharmaceutically acceptable salt or solvate thereof.

37. The compound of claim 1, which is a compound having any one of the following formulae:




90




or a pharmaceutically acceptable salt or solvate thereof.

38. The compound of claim 1, which is a compound having the following formula:



or a pharmaceutically acceptable salt or solvate thereof.

39. The compound of claim 1, which is a compound having the following formula:



20

or a pharmaceutically acceptable salt or solvate thereof.

40. A pharmaceutical composition comprising the compound of any one of claims 1 to 39 and a pharmaceutically acceptable excipient.
41. The compound of any one of claims 1 to 39 or the pharmaceutical composition of claim 40 for use in the treatment or prevention of cancer.
42. The compound for use according to claim 41 or the pharmaceutical composition for use according to claim 41, wherein the cancer is selected from gastrointestinal cancer, colorectal cancer, colon cancer, liver cancer, hepatocellular carcinoma, pancreatic cancer, biliary tract cancer, stomach cancer, genitourinary cancer, bladder cancer, testicular cancer, cervical cancer, malignant mesothelioma, osteogenic sarcoma, esophageal cancer, laryngeal cancer, prostate cancer, hormone-refractory prostate cancer, lung cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, triple-negative breast cancer, breast cancer having a BRCA1 and/or BRCA2 gene mutation, hematological cancer, leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, ovarian cancer, brain cancer, neuroblastoma, Ewing's sarcoma, kidney cancer, epidermoid cancer, skin cancer, melanoma, head and/or neck cancer, head and neck squamous cell carcinoma, and mouth cancer.

43. The compound for use according to claim 41 or 42 or the pharmaceutical composition for use according to claim 41 or 42, wherein the cancer is selected from colorectal cancer, colon cancer, pancreatic cancer, lung cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, melanoma, head and/or neck cancer, and head and neck squamous cell carcinoma.
44. The compound for use according to any one of claims 41 to 43 or the pharmaceutical composition for use according to any one of claims 41 to 43, wherein the cancer is colorectal cancer, colon cancer, or pancreatic cancer.
45. The compound for use according to any one of claims 41 to 44 or the pharmaceutical composition for use according to any one of claims 41 to 44, wherein the compound or the pharmaceutical composition is to be administered in combination with an anticancer drug and/or in combination with radiotherapy and/or immunotherapy.
46. The compound for use according to any one of claims 41 to 44 or the pharmaceutical composition for use according to any one of claims 41 to 44, wherein the compound or the pharmaceutical composition is to be administered in combination with one or more anticancer drugs selected from: an angiogenesis inhibitor which is preferably a protease inhibitor, a fibroblast growth factor receptor kinase inhibitor, or a vascular endothelial growth factor receptor kinase inhibitor; a cytostatic drug which is preferably an antimetabolite; an antimitotic agent which is preferably a microtubule-stabilizing drug or an antimitotic alkaloid; an anti-tumor antibiotic; an alkylating agent which is preferably a nitrogen mustard or a nitrosourea; an endocrine agent which is preferably an adrenocorticosteroid, an androgen, an anti-androgen, an estrogen, an anti-estrogen, an aromatase inhibitor, a gonadotropin-releasing hormone agonist, or a somatostatin analog; a compound that targets an enzyme or receptor that is overexpressed and/or otherwise involved in a specific metabolic pathway that is misregulated in the tumor cell, wherein said compound is selected from ATP and GTP phosphodiesterase inhibitors, histone deacetylase inhibitors, protein kinase inhibitors, vascular endothelial growth factor receptor kinase inhibitors, fibroblast growth factor inhibitors, insulin-like growth factor receptor inhibitors, PI3K inhibitors and platelet-derived growth factor receptor kinase inhibitors; an aminopeptidase inhibitor; a proteasome inhibitor; a cyclooxygenase inhibitor; a topoisomerase inhibitor; a poly ADP ribose polymerase (PARP) inhibitor; or an epidermal growth factor receptor (EGFR) inhibitor/antagonist.

47. The compound for use according to claim 46 or the pharmaceutical composition for use according to claim 46, wherein the compound or the pharmaceutical composition is to be administered in combination with an antimitotic agent which is selected from paclitaxel, nab-paclitaxel, docetaxel, larotaxel, ortataxel, and tesetaxel.
48. The compound for use according to any one of claims 41 to 44 or the pharmaceutical composition for use according to any one of claims 41 to 44, wherein the compound or the pharmaceutical composition is to be administered in combination with folinic acid and 5-fluorouracil.
49. The compound for use according to any one of claims 41 to 44 or the pharmaceutical composition for use according to any one of claims 41 to 44, wherein the compound or the pharmaceutical composition is to be administered in combination with radiotherapy.
50. The compound for use according to any one of claims 41 to 44 or the pharmaceutical composition for use according to any one of claims 41 to 44, wherein the compound or the pharmaceutical composition is to be administered in combination with immunotherapy.
51. The compound for use according to any one of claims 41 to 44 or the pharmaceutical composition for use according to any one of claims 41 to 44, wherein the compound or the pharmaceutical composition is to be administered in combination with an immuno-oncology therapeutic targeting any one of CTLA-4, PD-1/PD-L1, TIM3, LAG3, OX4, CSF1R, IDO, or CD40.
52. The compound for use according to claim 51 or the pharmaceutical composition for use according to claim 51, wherein said immuno-oncology therapeutic is selected from: an anti-CTLA-4 antibody which is preferably ipilimumab or tremelimumab; an anti-PD-1 antibody which is preferably nivolumab, pembrolizumab, pidilizumab, AMP-224, or APE02058; an anti-PD-L1 antibody which is preferably BMS-936559, MEDI4736, MPDL3280A, MDX-1105, or MEDI6469; an anti-TIM3 antibody; an anti-LAG3 antibody which is preferably BMS-986016, IMP701, or IMP731; an anti-OX4 antibody which is preferably MEDI0562; an anti-CSF1R antibody which is preferably IMC-CS4 or RG7155; an anti-IDO antibody; or an anti-CD40 antibody which is preferably CP-870,893 or Chi Lob 7/4.